Esketamine Therapy
Skyland Trail offers SPRAVATO, esketamine nasal spray, to adults with depression enrolled in our residential or day treatment programs. SPRAVATO has been proven safe and effective for adults with medication-resistant depression or depression with acute suicidal ideation or behavior.
Says Dr. Ben Hunter, Charles B. West Chief Medical Officer, "SPRAVATO can be a treatment accelerator, helping patients with depression or with suicide ideation experience quicker, more robust results."
Some studies suggest that SPRAVATO can be more effective for treatment-resistant depression than some commonly prescribed medications. SPRAVATO can be administered onsite in the Skyland Trail Glenn Family Wellness Clinic when clinically appropriate and prescribed by a Skyland Trail psychiatrist.
SPRAVATO can be used in conjunction with psychotherapy and antidepressant medications or TMS to help patients with persistent depression. Residential treatment is an ideal environment for patients to receive a combination of these therapies. Patients receive 24/7 support and observation from a multidisciplinary treatment team. The patient’s treatment team can contribute more data to inform treatment decisions. And treatments can be adjusted and optimized in real-time to achieve the best possible results while minimizing side effects.
Your Esketamine Questions Answered
SPRAVATO is esketamine therapy administered as a nasal spray. SPRAVATO must be prescribed by a psychiatric provider. SPRAVATO has been proven safe and effective for adults with medication-resistant depression or depression with acute suicidal ideation or behavior.
Esketamine, or SPRAVATO, has been proven safe and effective for adults with medication-resistant depression or depression with acute suicidal ideation or behavior.
SPRAVATO can be a treatment accelerator, helping patients with depression and/or SI experience quicker, more robust results.
SPRAVATO can be used in conjunction with psychotherapy and antidepressant medications or TMS to help patients with persistent depression.
SPRAVATO is an esketamine nasal spray. The medication is self-administered under supervision in the Skyland Trail Glenn Family Wellness Clinic. After administration, the patient rests comfortably in the Wellness Clinic and is monitored for two hours with periodic blood pressure checks. The patient can then return to the client community.
At Skyland Trail, SPRAVATO is delivered in 2 hour sessions. For the first month, the patient has two sessions per week. For the second month, the patient has one session per week. After the second month, maintenance sessions are prescribed as needed.
Esketamine and ketamine are related, but have different chemical compostions. They also have different indications and are administered differently.
Esketamine is FDA-approved antidepressant for the treatment of treatment-resistant depression and suicide ideation in adults. Esketamine is a nasal spray that is self-administered under supervision. Esketamine is administered only in a physician's office with a strict treatment protocol enforced by a mandatory Risk Evaluation and Mitigation Strategy program.
Ketamine is a dissociative anesthetic. Currently, ketamine is only approved in the U.S. for the purposes of anesthesia. Ketamine currently is not indicated for major depressive disorder or treatment-resistant depression, though a physician may prescribe it "off label." Ketamine is typically administered through an IV or injection. Ketamine is more likely to be used as a recreational substance than esketamine.